A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs
ABSTRACT The toxicity of tenofovir alafenamide (TAF) hemifumarate (HF) was evaluated when administered by continuous subcutaneous (s.c.) infusion via an external infusion pump for 28 days to rats and dogs. The toxicokinetics of TAF and two metabolites, tenofovir (TFV) and tenofovir diphosphate (TFV-...
Main Authors: | Doris Zane, Shane Roller, Josephine Shelton, Roshni Singh, Rachna Jain, Yan Wang, Bing Yang, Melanie Felx, Thomas Alessi, Paul L. Feldman |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2021-09-01
|
Series: | Microbiology Spectrum |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/Spectrum.00339-21 |
Similar Items
-
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
by: Bernard Surial, et al.
Published: (2019-10-01) -
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
by: Hung-Yao Lin, et al.
Published: (2022-04-01) -
Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01) -
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01) -
Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV
by: Michał Łomiak, et al.
Published: (2023-09-01)